Phenylpropanolamine: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
CSV import
Line 44: Line 44:
[[Category:Decongestants]]
[[Category:Decongestants]]
[[Category:Withdrawn drugs]]
[[Category:Withdrawn drugs]]
==Phenylpropanolamine==
<gallery>
File:Phenylpropanolamine.svg|Phenylpropanolamine
File:Phenylpropanolamine molecule ball.png|Phenylpropanolamine molecule ball
File:Phenylpropanolamine spacefill.png|Phenylpropanolamine spacefill
</gallery>

Revision as of 01:07, 20 February 2025

Overview of Phenylpropanolamine


Phenylpropanolamine
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG


Phenylpropanolamine (PPA) is a sympathomimetic agent used as a decongestant and appetite suppressant. It is a member of the phenethylamine class and is structurally related to ephedrine and amphetamine.

Pharmacology

Phenylpropanolamine acts primarily as an alpha-adrenergic receptor agonist, leading to vasoconstriction and decreased nasal congestion. It also has some activity as a beta-adrenergic receptor agonist, which contributes to its effects on appetite suppression.

Medical Uses

Phenylpropanolamine was commonly used in over-the-counter cold medications and weight loss products. It was effective in reducing nasal congestion and suppressing appetite.

Safety and Regulation

In the early 2000s, concerns about the safety of phenylpropanolamine led to its withdrawal from the market in many countries. Studies indicated an increased risk of hemorrhagic stroke in women using the drug. As a result, the U.S. Food and Drug Administration (FDA) issued a public health advisory in 2000, recommending that consumers not use products containing phenylpropanolamine.

Current Status

Phenylpropanolamine is no longer available in the United States and many other countries for human use. However, it is still used in veterinary medicine, particularly for the treatment of urinary incontinence in dogs.

Mechanism of Action

Phenylpropanolamine works by stimulating the release of norepinephrine and dopamine from nerve terminals, which leads to increased adrenergic activity. This results in vasoconstriction and reduced blood flow to the nasal passages, alleviating congestion.

Side Effects

Common side effects of phenylpropanolamine include increased heart rate, elevated blood pressure, anxiety, dizziness, and insomnia. Due to its stimulant effects, it can also lead to tachycardia and hypertension.

History

Phenylpropanolamine was first introduced in the 1930s and became widely used in the 1970s and 1980s. Its popularity declined after safety concerns emerged, leading to regulatory actions in the 1990s and 2000s.

Also see

References

<references group="" responsive="1"></references>

Phenylpropanolamine